Evidence map›Paper›PMID 31780660›Full record

ArticleBlood cancer journal2019

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma.

Jeffrey Wang, Jacqueline Wang, Elyse Lopez, Hui Guo, Hui Zhang, Yang Liu, Zhihong Chen, Shengjian Huang, Shouhao Zhou, Angela Leeming and 13 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Redox regulation of immunometabolism.Nature reviews. Immunology · 2021
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Jeffrey WangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jacqueline WangDepartment of Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elyse LopezDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hui GuoDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hui ZhangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yang LiuDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhihong ChenDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shengjian HuangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shouhao ZhouDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Angela LeemingDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
R J ZhangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dayoung JungDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1203-3737
Hannah ShiDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hadley GrundmanDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Darian DoakesDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kathleen CuiDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Changying JiangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Makhdum AhmedDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Krystle NomieDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bingliang FangDepartment of Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael WangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9748-5486
Yixin YaoDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-8439-6043
Liang ZhangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. liazhang@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Super-Resolution OMX MicroscropeS10RR029552 · NCRR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZAL, TOMASZ · 2011 to 2011
$1.0M
NCI NIH HHS P30 CA016672NCRR NIH HHS S10 RR029552
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MutationAntineoplastic AgentsApoptosisAuranofinCaspasesCell Line, TumorCell SurvivalDNA DamageDrug RepositioningDrug Resistance, NeoplasmHumansLymphoma, B-CellPTEN PhosphohydrolaseReactive Oxygen SpeciesTumor Suppressor Protein p53Antineoplastic AgentsAuranofinCaspasesPTEN PhosphohydrolasePTEN protein, humanReactive Oxygen SpeciesTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID31780660
PMCPMC6882812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.